Evidence map›Paper›PMID 32173576›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.

Fang Liu, Aifang Xu, Yan Zhang, Weiling Xuan, Tingbo Yan, Kenv Pan, Wenyan Yu, Jun Zhang

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04353271 (A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics), which is not on this map. Cited by 193 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 21 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04353271 phase2 / phase3terminatednot on this map

A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics

TypeinterventionalSponsorUniversity of South AlabamaRan2020 to 2020Enrolled3ConditionsCovid 19, Corona Virus InfectionArmsHydroxychloroquine, Placebo
3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 21 syntheses or guidelines pooled it, 362 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Guidelines: Anaesthesia in the context of COVID-19 pandemic.Anaesthesia, critical care & pain medicine · 2020
    Guideline
  19. Pooled it
  20. Pooled it

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fang LiuMedical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China.
Aifang XuMedical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China.
Yan ZhangMedical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China; Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Weiling XuanDepartment of Radiology, Xixi Hospital of Hangzhou, Hangzhou, China.
Tingbo YanDepartment of Radiology, Xixi Hospital of Hangzhou, Hangzhou, China.
Kenv PanMedical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China.
Wenyan YuMedical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China.
Jun ZhangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: jameszhang2000@zju.edu.cn.
Hangzhou Xixi hospital · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the epidemiological information, clinical characteristics, therapeutic outcomes and temporal progression of laboratory findings in 2019-coronavirus disease (COVID-19) patients exposed to lopinavir.

methodsWe collected data from ten COVID-19 patients admitted between January 22, 2020 and February 11, 2020 at Xixi hospital in Hangzhou, China.

resultsOf ten patients, secondary, tertiary and quartus patients emerged; the incubation period was 3-7 days. Mainly initial symptoms were cough and low fever (37.3-38.0°C). An asymptomatic case presented normal radiography, the others had ground glass opacities. All cases (three transferred, seven discharged) were exposed to lopinavir on initial hospitalization. Three patients stopped lopinavir because of adverse effects, two of them deteriorated, one was hospitalized longer than others who with sustained lopinavir use. Levels of potassium, albumin, and lymphocytes were low, but increased persistently after treatment. Eosinophil values were low on initial hospitalization, then all returned to normal before discharge. Viral load of SARS-CoV-2, radiography and eosinophil improved continuously in 3-14, 6-8 and 7-9 days, respectively.

conclusionsIncreasing eosinophils may be an indicator of COVID-19 improvement. The COVID-19 patients may benefit from sustained lopinavir use. More research on a larger scale is needed to verify these points.

Indexed as

BetacoronavirusEosinophilsCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDisease ProgressionDrug Therapy, CombinationFemaleHumansLopinavirMaleMiddle AgedPandemicsPneumonia, ViralSARS-CoV-2Lopinavir2019-Coronavirus diseaseAsymptomatic infectionEosinophilLopinavir

Identifiers

PMID32173576
PMCPMC7193136
OpenAlexW3011955243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.